GW501516 (Cardarine): A PPARδ Agonist for Metabolic Research
GW501516, also known as Cardarine or Endurobol, is a potent synthetic PPARδ agonist developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s. Although clinical development was halted in 2007 due to rapid cancer development observed in multi-dose rodent studies, the compound remains extensively used in basic metabolic research as a tool to probe fatty acid oxidation pathways, endurance physiology, and lipid metabolism. It is critical to note that GW501516 is not a SARM and does not act on androgen receptors.
Mechanism: Activating the Fatty Acid Oxidation Switch
PPARδ is a transcription factor expressed in skeletal muscle, heart, liver, and adipose tissue. When activated by GW501516, it upregulates genes involved in fatty acid catabolism — particularly in skeletal muscle, where it shifts substrate utilization from glucose toward fatty acids. Narkar et al. (2008) demonstrated in a landmark Cell paper that GW501516, when combined with exercise training, dramatically increased running endurance in mice through PPARδ-driven reprogramming of skeletal muscle gene expression. [PMID: 18674809]
Earlier work by Dressel et al. (2003) characterized GW501516’s mechanism of PPARδ transactivation and its downstream effects on lipid metabolism in muscle, establishing the basis for its use in metabolic research designs. [PMID: 14525954]
Research Applications
GW501516 is widely used in studies examining: fatty acid metabolism in muscle and liver; HDL modulation and reverse cholesterol transport; endurance performance in rodent treadmill models; and interactions with SARMs in combined anabolic-metabolic study designs. Its reliable activation of metabolic gene expression makes it a useful positive control compound in PPARδ pathway research.
Safety Note
Research-grade GW501516 must be handled with appropriate precautions given its carcinogenicity findings in animals. It is prohibited by WADA and listed as a Schedule 10 substance by Australia’s TGA. All use must be within authorized laboratory research protocols with appropriate institutional oversight. For metabolic research that avoids these concerns, researchers sometimes use GW0742, a related PPARδ agonist, or SR9009 (Stenabolic), which targets the Rev-ErbA pathway through a distinct mechanism.
Chemyo GW501516 Products
For laboratory research use only.
